Why the study?
Does treatment with a mAb against LFA-1 prevent the death of transplanted myoblasts in mice?
Does treatment with a mAb against LFA-1 prevent the death of transplanted myoblasts in mice?
Controlling the nonspecific inflammatory reaction with anti-LFA-1 and specific immune response with FK506 significantly increases the success of myoblast transplantation in a mouse model.
Answers are grounded in this paper and cite their sources.
May improve myoblast engraftment in immunosuppressed mice; leaves open translation to clinical cell therapy.
Myoblast transplantation is a potential treatment for Duchenne Muscular Dystrophy. This article confirms by experiments in mice that one problem that has limited the success of clinical trials of this procedure is a rapid (within 3 days) inflammatory reaction which kills most of the injected myoblasts. The death of the transplanted myoblasts can be prevented by treating the host with a mAb against LFA-1. This led to a 27-fold increase in the number of muscle fibers expressing a reporter gene present in the donor myoblasts when the host is also adequately immunosuppressed with FK506. Therefore, both the nonspecific inflammatory reaction and the specific immune response should be adequately controlled following myoblast transplantation.
No takes yet. Share an insight, caveat, or question.
Guérette et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: